摘要
目的:观察重组人血管内皮抑制素(恩度)联合放化疗治疗肺癌的近期疗效及毒副反应。方法:经病理学确诊的肺癌患者16例,平均年龄57.2岁,接受恩度治疗同时联合NP、GP或EC方案的全身化疗及体部伽玛刀治疗,其中恩度治疗2-7个周期,平均3.3个周期,非小细胞癌患者化疗用NP、GP方案,小细胞癌患者用CE方案,每组患者均完成2-6个周期化疗,平均2.8个周期。体部伽玛刀治疗局部病灶3.3Gy-4.3Gy/次,共10-12次,靶区总剂量36Gy-46Gy。按照RECIST标准评价近期疗效,参照Karnofsky评分标准(KPS)评价生活质量(QOL)。结果:全组16例患者近期疗效:CR 3例,PR 9例,SD 3例,PD 1例。临床有效率(CR+PR)75%(12/16)。疾病控制率(DCR)94%(15/16)。生活质量评价6例QOL改善,7例QOL稳定,3例患者出现QOL下降。毒副反应较轻,经对症处理均可缓解。结论:恩度与放化疗联合治疗肺癌疗效较好。具有协同作用,安全性亦较好,毒副作用可以耐受。
Objective：To evaluate the clinical implication of recombinant human endostatin（Endostar） in combination with radiotherapy and chemotherapy in lung cancer.Methods： Sixteen patients with lung cancers were treated with endostatin injection generally 2-7cycles combined with stereotactic radiotherapy and chemotherapy（The total dose was 36Gy-46Gy /10-12f） and NP,GP or EC chemotherapy treatment（generally 2-6 cycles）.Results： All 16 patients had completed the treatment.The DCR was 94%（15/16）.6 cases improved their QOL,7 cases were stable,3 cases were declined in their QOL.The side reactions were mild and tolerable.Conclusion： Endostatin combined body gamma-knife and chemotherapy is safe and effective in the treatment of advanced lung cancers.The adverse events are tolerable.
出处
《现代肿瘤医学》
CAS
2012年第6期1192-1194,共3页
Journal of Modern Oncology
关键词
重组人血管内皮抑制素
恩度
肺癌
立体定向放疗
化疗
recombinant human endostatin
endostar
lung cancer
stereotactic radiotherapy
chemotherapy
